Clinical Trial Update: Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating TU2218 in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors is currently recruiting, includ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• TU2218

Snippet

Sponsor: TiumBio Co., Ltd. | Conditions: Solid Tumor, Biliary Tract Cancer | Phase 1, Phase 2 | Status: RECRUITING